Our data are similar to that recently reported (Kim et al., 2014); they demonstrate that a variety of anti-cancer agents are more effective in RhoJ-knockout mice, suggesting that inhibition of RhoJ signalling might have therapeutic benefit. Here, RHOJ is linked to cancer.